vaccines infectious

advertisement
Posters –
Infectious diseases and Vaccines
NAME OF THE PROJECT
NAME OF THE MAIN CONTACT
ORGANISATION NAME
Easy Vaccine Production
Rémi PICARD
SATT Sud Est
Combination of two novel methodologies for improved vaccine production:
1) Obtention of attenuated virus (with a controlled attenuation level), by a
randomized but controlled re-encoding approach
2) Production of infectious virus by infectious-subgenomic-amplicons (ISA)
produced by RT-PCR on the whole viral genome
Technology
Customers / Target market
Competitive advantages:
- Control of undesired genomic mutations and of viral attenuation levels
- No possible escape by reversion (reversion level does not exceed 0.34% even after 200
cell cycles)
- No problem of clonal diversity, and high stability of the attenuated generated viruses
- Very low probability of recombination with a wild strain
- 1-month production (versus 5 months with standard method)
- Significant decrease of production costs (5-fold)
An advanced preparation method for:
 Production of human and veterinary attenuated single-stranded RNA viruses
 Possible extension of the method to DNA viruses
Advanced vaccine production techniques are expected by pharmaceutical industry.
Industry and competitors
Financing need / Commercial
opportunity
IP – Patent situation
Future steps / Milestones
2 types of vaccines are currently available:
- Attenuated viruses (modification of the viruses’ phenotype) but attenuation level is
difficult to control: our innovative technique addresses this issue.
- Inactivated viruses are highly expensive as well as difficult to obtain and show limited
efficiency on a short period (require multiple injections)
We are currently looking for an industrial partner interested for licensing-in the
technology and/or R&D collaboration (possible co-funding)
Patent: PCT application (June 2015)
N/A
Further reading
Developed by Pr. Xavier DE LAMBALLERIE’s team, at “Viral Diseases Emergence” Lab
(UMR_D 190, Medicine University of Marseille, France), scientific key opinion leader in
vaccinology
Contact person
Elodie
Dormes,
Business
elodie.dormes@sattse.com
Development
Manager,
SATT
Sud
Est,
Download